Testing a blood marker miR-1 in muscle diseases and healthy people
Measures blood levels of miR-1 to see if it tracks muscle disease progression.
Plain-language title generated from the registry record
Registry title: Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies
Key facts
- Where
- Clermont-Ferrand, FranceSee the site
Where in France
- CHU de Clermont-FerrandClermont-Ferrand, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Clermont-Ferrand
- Trial code
- NCT07415837
- Record updated
- 25 February 2026
- Original description
The study aims to find out if a specific blood molecule called miR-1, can be used as a biomarker to track the health of patients with certain muscle diseases.Read full original descriptionShow less
Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies
The study aims to find out if a specific blood molecule called miR-1, can be used as a biomarker to track the health of patients with certain muscle diseases.
MicroRNAs (miRs) are small messengers that help control how cells grow and stay healthy. Some of these, like miR-1, are specifically found in muscles and the heart. Research shows that levels of miR-1 are often abnormal in people with muscle-wasting conditions, but more information are needed to understand how this relates to the severity of the disease.
The main goal is to compare the blood levels of miR-1 between four different groups at different ages and severities:
1. Patients with Duchenne or Becker muscular dystrophy (DMD/DMB). 2. Patients with Myotonic Dystrophy Type 1 (Steinert's disease). 3. Patients with congenital myopathies. 4. Healthy volunteers (control group). The main objective is to assess if miR-1 levels can accurately show how a muscular disease is progressing.
Inclusion: Age: Participants must be older than 2 years of age; Consent: Participants (or their legal guardians) must provide free and informed consent,. For children, the consent is oral for those under 6 years old and written for those over 6,; Social Security: Every participant must be affiliated with the French social security system; Participants must have a diagnosed neuromuscular pathology : the eligible pathologies are Myotonic Dystrophy Type 1 (DM1 or Steinert's disease), Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (DMB), or congenital myopathies or are healthy participants.
Exclusion: Engaging in intense and unusual physical effort within 10 days before the blood draw; Current use of any treatment with systemic, muscular, or cardiac effects that could interfere with the study's biological results; Refusal to participate expressed by the subject or their parental authority; Subjects or their legal guardians who are under tutelage, curatorship, deprived of liberty, or under judicial protection; Women who are pregnant or breastfeeding; The presence of an additional pathology that, in the judgment of the clinician, could interfere with the biological findings.